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HTLV-1 Associated Myelopathy/Tropical spastic parapar-
esis (HAM/TSP) is the classical neurological syndrome
associated with this retrovirus, although other neurological
complications are described. We collected data in the neu-
rological and epidemiological databases related of the
GIPH cohort, from 1997 and 2012, as well as in the
records of the participants. Statistics involved a 95% confi-
dence interval (CI). The main neurological outcomes pre-
sented by seropositive patients in the cohort were
described and a comparison between groups of patients
with and without HAM/TSP was performed with regard
to other clinical manifestations. Among the 255 cohort
participants examined by a neurologist, 233 (91%) were
positive for HTLV-1 (CI 88-95%). From those, 12% had
HAM/TSP (CI 8-16%), 20% had low back pain (CI 15-
25%); 18% were diagnosed with depression, cramps and
fatigue (CI 13-23%); 14% had myalgia (CI 10-18%); 13%
had acute pain (CI 9-17%), 11% had urinary incontinence
(CI 7-15%) and 10% had hearing loss (CI 6-14%). Compar-
ing groups of patients with and without HAM/TSP, we
found that symptomatic myelopathy patients had a greater
chance of developing events such as urinary retention
(RR= 9.8), gait abnormalities (RR= 7.3), constipation (RR=
6.7), urinary incontinence (RR= 5.0), sexual dysfunction
(RR= 3.2), fatigue (RR= 2.9) and myalgia (RR= 2.7), when
compared with asymptomatic to HAM/TSP (p<0.0001). In
conclusion, 12% of patients developed HAM/TSP, which
is a higher rate than that described in the literature.
Furthermore, we found that patients with HAM/TSP had
higher risk to develop other neurological outcomes related
to this virus infection.
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